Tramadol half-life

Tramadol labeling supports a parent half-life near six hours, while the active O-desmethyltramadol metabolite persists somewhat longer and depends on CYP2D6 formation.

Category: opioid · Updated: August 7, 2026

Sources and model notes are maintained by . This page is educational, not clinical guidance. Corrections: admin@halflifedb.co.

Model status6 hTramadol · same-day representative value
Reported rangeNot displayedPublished when the current evidence record supports a readable range
Model scopeRelative declineNormalized first-order model, not an in-body concentration estimate
References2Linked studies, labels, reviews, or identity records described below
Relative starting point
100%

Every curve begins at 100%. No dose or measured body concentration is assumed.

0m6h12h18h24h30h0%25%50%75%100%X-axis: elapsed timeY-axis: amount remaining (%)

X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. This is a mathematical visualization, not a personal concentration estimate.

Modeled remaining: 50.0%Half-life used: 6 h

Tramadol: evidence and interpretation notes

Parent drug, metabolites, and formulation

Tramadol labeling supports a parent half-life near six hours, while the active O-desmethyltramadol metabolite persists somewhat longer and depends on CYP2D6 formation. Both facts matter more than the parent line by itself.

The plotted input is 6 hours for Tramadol. It is a normalized comparison line, not a reconstruction of a measured blood concentration or a forecast of effects.

Tramadol combines opioid activity with monoaminergic mechanisms, and its active metabolite makes CYP2D6 context important.

The 6 hour value is a parent-drug educational input. It does not model O-desmethyltramadol, seizure risk, serotonin toxicity, or analgesic response.

The citations include a direct DailyMed tramadol label and the compound record.

Do not use this page for medication timing, dosing, or safety decisions.

For Tramadol, parent-drug decline should be read separately from analgesia, respiratory risk, metabolites, and formulation. Opioid risk is not proportional to the percentage remaining in this simplified chart.

What each source contributes

  • DailyMed: Tramadol hydrochloride tablet. This product label adds formulation-specific pharmacokinetic context and does not represent every route or product.
  • PubChem: Tramadol. This identity record confirms names and compound identity and does not supply a human half-life.

For Tramadol, the numerical model is tied most closely to DailyMed: Tramadol hydrochloride tablet. As a product label, it adds formulation-specific pharmacokinetic context; it does not represent every route or product.

Why there is no range on the chart

This profile plots 6 hours for Tramadol without adding an unsourced high-low band. A single supported center is more honest than manufacturing a range from unrelated routes, populations, or formulations.

InterpretationReading the curve and its category context

Reading this curve

HalfLifeDB uses 6 h as a representative input for Tramadol. In the simplified model, about 6.3% remains after 24 hours and about 3% remains after five half-lives, or roughly 30 h.

This sits in the same-day range. The chart is useful for seeing the bend of the curve across a day or two, but it should not be treated as a personal clock. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.

opioid context

Opioid pharmacokinetics can differ between parent compounds and metabolites, and timing can vary by route, formulation, and individual clearance.

  • Half-life is not a measure of respiratory risk or functional impairment.
  • Active metabolites can matter even when the parent compound declines.
  • Extended-release products require separate source context.
ComparisonTimeline checkpoints and nearby profiles

Tramadol timeline checkpoints

Elapsed timeModeled remainingReading note
12 h25.0%Long-tail portion of the model
24 h6.25%Low modeled remainder, not a clearance guarantee
2.0 days0.39%Low modeled remainder, not a clearance guarantee
3.0 days0.02%Low modeled remainder, not a clearance guarantee
5.0 days0.00%Low modeled remainder, not a clearance guarantee

Nearby profiles by half-life

These entries sit near Tramadol within the opioid group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.

EvidencePharmacokinetic inputs and source trail

Pharmacokinetics at a glance

Representative half-life6 h
Curve typeNormalized, first-order decline

Selection note: Tramadol labeling supports a parent half-life near six hours, while the active O-desmethyltramadol metabolite persists somewhat longer and depends on CYP2D6 formation. Both facts matter more than the parent line by itself.

Sources and evidence context

A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.

0 PubMed0 PMC1 DailyMed1 PubChem
  1. Official labeling DailyMed label: Tramadol hydrochloride tablet.
    Official U.S. product labeling used for formulation and labeled pharmacokinetic context; its statements apply to the described product.
  2. Identity record PubChem Compound Summary: Tramadol.
    Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
BoundariesWhat this page cannot answer and where to continue

What this page does not answer

  • It does not estimate impairment, intoxication, or fitness to drive.
  • It does not predict urine, blood, saliva, or hair test results.
  • It does not model repeated exposure, tolerance, withdrawal, or interactions.
  • It does not replace clinician, pharmacist, toxicologist, or emergency guidance.

Continue with context

Read the medical disclaimer, methodology, and research standards before using the model for comparison.